{
    "info": {
        "nct_id": "NCT03899467",
        "official_title": "An Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Who Failed Either Abiraterone or Enzalutamide",
        "inclusion_criteria": "Inclusion criteria:\n\n1. Signed informed consent obtained prior to any study-related procedure being performed.\n2. Subjects at least 18 years of age or older at the time of consent.\n3. Subjects with histologically confirmed mHSPC or mCRPC who received abiraterone or enzalutamide for the hormonal treatment of 6 months or longer.\n4. Subjects with mHSPC are required to have no prior ADT (androgen deprivation therapy) or orchiectomy. For mCRPC, ongoing androgen deprivation therapy with a luteinizing hormonereleasing hormone (LHRH) \"super-agonist\" or antagonist, or bilateral orchiectomy. Serum testosterone level is < 50 ng/dL (< 0.5 ng/mL, < 1.7 nmol/L) at screening.\n5. Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.\n6. Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both. However, if either of these 2 drugs was used less than 3 months due to toxicity, the patient is eligible. One line of chemotherapy is eligible. Progressive disease is defined by 1 or more of the following criteria:\n\n   1. Subjects with a rising prostate specific antigen (PSA) value > 2 ng/mL in at least 2 measurements, at least 1 week apart. If the confirmatory PSA value is less than the screening PSA value, then an additional test for the rising PSA is required to document progression.\n   2. Subjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n   3. Subjects with metastatic bone disease, progression defined by 2 or more new lesions in a radionuclide bone scan.\n7. ECOG performance status of 0-1\n8. Screening blood counts of the following:\n\n   1. Absolute neutrophil count ≥ 1500/μL\n   2. Platelets ≥ 100,000/μL\n   3. Hemoglobin > 9 g/dL (if asymptomatic).\n9. Screening chemistry values of the following:\n\n   1. Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper limit of the normal reference range (ULN)\n   2. Total bilirubin ≤ 2 × ULN\n   3. Creatinine ≤ 1.5 × ULN\n   4. Albumin > 2.8 g/dL.\n10. At screening, life expectancy of at least 6 months.\n11. Subjects whose partners are women of childbearing potential (WOCBP) must use an adequate method of birth control while on study drug and for at least 3 months after discontinuation of study drug.\n12. Subject is willing and able to comply with all protocol required visits and assessments.\n\nExclusion criteria:\n\n1. Discontinuation of enzalutamide or abiraterone less than 3 weeks prior to the start of study medication.\n2. Prior chemotherapy and experimental therapy (Poly (ADP-ribose) polymerase (PARP) or checkpoint inhibitor)\n3. Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy.\n4. History of impaired adrenal gland function (e.g., Addison's disease, Cushing's syndrome).\n5. Known gastrointestinal disease or condition that affects the absorption of proxalutamide.\n6. History of congestive heart failure New York Heart Association (NYHA) class III or IV or uncontrolled hypertension at screening.\n7. History or family history of long QT syndrome, or ECG corrected QT interval equal to and over 500 ms (CTCAE grade 2) at baseline.\n8. History of other malignancy within the previous 3 years, except basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.\n9. Use of systemic glucocorticoid (e.g., prednisone, dexamethasone) within 14 days prior to the start of study medication. Inhaled or topical steroids are allowed.\n10. Co-administration of CYP3A4 ligands that serve as substrates or induce or inhibit the enzyme.\n11. Prior use of any herbal products known to decrease PSA levels (e.g., PC-SPES or saw palmetto) within 30 days prior to the start of study medication.\n12. Major surgery within 30 days prior to the start of study medication.\n13. Blood transfusion (including blood products) within 1 week of screening.\n14. Serious persistent infection within 14 days prior to the start of study medication.\n15. Serious concurrent medical condition including CNS disorders.\n16. Previous history of difficulty swallowing capsules.\n17. Known hypersensitivity to GT0918 or its excipients.\n18. Any condition that, in the opinion of the investigator, would impair the subject's ability to comply with study procedures.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Signed informed consent obtained prior to any study-related procedure being performed.",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent obtained prior to any study-related procedure being performed.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study-related procedure"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subjects at least 18 years of age or older at the time of consent.",
            "criterions": [
                {
                    "exact_snippets": "at least 18 years of age or older at the time of consent",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age at time of consent",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects with histologically confirmed mHSPC or mCRPC who received abiraterone or enzalutamide for the hormonal treatment of 6 months or longer.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed mHSPC or mCRPC",
                    "criterion": "prostate cancer type",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "mHSPC",
                                "mCRPC"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "received abiraterone or enzalutamide for the hormonal treatment of 6 months or longer",
                    "criterion": "hormonal treatment with abiraterone or enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "treatment_received",
                            "expected_value": [
                                "abiraterone",
                                "enzalutamide"
                            ]
                        },
                        {
                            "requirement_type": "treatment_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.",
            "criterions": [
                {
                    "exact_snippets": "Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation_method",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)",
                                "bone scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects with mHSPC are required to have no prior ADT (androgen deprivation therapy) or orchiectomy. For mCRPC, ongoing androgen deprivation therapy with a luteinizing hormonereleasing hormone (LHRH) \"super-agonist\" or antagonist, or bilateral orchiectomy. Serum testosterone level is < 50 ng/dL (< 0.5 ng/mL, < 1.7 nmol/L) at screening.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with mHSPC are required to have no prior ADT (androgen deprivation therapy) or orchiectomy.",
                    "criterion": "prior ADT or orchiectomy in mHSPC subjects",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "For mCRPC, ongoing androgen deprivation therapy with a luteinizing hormonereleasing hormone (LHRH) \"super-agonist\" or antagonist, or bilateral orchiectomy.",
                    "criterion": "androgen deprivation therapy or bilateral orchiectomy in mCRPC subjects",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": [
                                "ongoing androgen deprivation therapy with LHRH super-agonist or antagonist",
                                "bilateral orchiectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum testosterone level is < 50 ng/dL (< 0.5 ng/mL, < 1.7 nmol/L) at screening.",
                    "criterion": "serum testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0.5,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.7,
                                "unit": "nmol/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both. However, if either of these 2 drugs was used less than 3 months due to toxicity, the patient is eligible. One line of chemotherapy is eligible. Progressive disease is defined by 1 or more of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both.",
                    "criterion": "hormonal treatment with abiraterone or enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "treatment_history",
                            "expected_value": [
                                "abiraterone",
                                "enzalutamide"
                            ]
                        },
                        {
                            "requirement_type": "number_of_drugs_used",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if either of these 2 drugs was used less than 3 months due to toxicity, the patient is eligible.",
                    "criterion": "duration of abiraterone or enzalutamide use due to toxicity",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "reason_for_discontinuation",
                            "expected_value": "toxicity"
                        }
                    ]
                },
                {
                    "exact_snippets": "One line of chemotherapy is eligible.",
                    "criterion": "prior chemotherapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number_of_lines",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Subjects with a rising prostate specific antigen (PSA) value > 2 ng/mL in at least 2 measurements, at least 1 week apart. If the confirmatory PSA value is less than the screening PSA value, then an additional test for the rising PSA is required to document progression.",
            "criterions": [
                {
                    "exact_snippets": "rising prostate specific antigen (PSA) value > 2 ng/mL in at least 2 measurements, at least 1 week apart",
                    "criterion": "prostate specific antigen (PSA) value",
                    "requirements": [
                        {
                            "requirement_type": "trend",
                            "expected_value": "rising"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "number of measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "measurements"
                            }
                        },
                        {
                            "requirement_type": "time between measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If the confirmatory PSA value is less than the screening PSA value, then an additional test for the rising PSA is required to document progression",
                    "criterion": "PSA progression confirmation",
                    "requirements": [
                        {
                            "requirement_type": "additional test required if confirmatory PSA < screening PSA",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria",
            "criterions": [
                {
                    "exact_snippets": "measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects with metastatic bone disease, progression defined by 2 or more new lesions in a radionuclide bone scan.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with metastatic bone disease",
                    "criterion": "metastatic bone disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progression defined by 2 or more new lesions in a radionuclide bone scan",
                    "criterion": "progression of bone disease",
                    "requirements": [
                        {
                            "requirement_type": "number of new lesions on radionuclide bone scan",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. ECOG performance status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Screening blood counts of the following:",
            "criterions": [
                {
                    "exact_snippets": "Screening blood counts",
                    "criterion": "blood counts",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": "screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute neutrophil count ≥ 1500/μL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1500/μL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelets ≥ 100,000/μL",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 100,000/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hemoglobin > 9 g/dL (if asymptomatic).",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 9 g/dL (if asymptomatic)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper limit of the normal reference range (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 × upper limit of the normal reference range (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate transaminase (AST) ≤ 2.5 × upper limit of the normal reference range (ULN)",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Total bilirubin ≤ 2 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 2 × ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Creatinine ≤ 1.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Creatinine ≤ 1.5 × ULN",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Screening chemistry values of the following:",
            "criterions": [
                {
                    "exact_snippets": "Screening chemistry values",
                    "criterion": "screening chemistry values",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": "provided for the following analytes (not specified in this line)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Albumin > 2.8 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Albumin > 2.8 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. At screening, life expectancy of at least 6 months.",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of at least 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Subjects whose partners are women of childbearing potential (WOCBP) must use an adequate method of birth control while on study drug and for at least 3 months after discontinuation of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Subjects whose partners are women of childbearing potential (WOCBP)",
                    "criterion": "partner's childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner is woman of childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use an adequate method of birth control while on study drug and for at least 3 months after discontinuation of study drug",
                    "criterion": "birth control method usage",
                    "requirements": [
                        {
                            "requirement_type": "use of adequate birth control method",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "while on study drug"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after discontinuation of study drug"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Subject is willing and able to comply with all protocol required visits and assessments.",
            "criterions": [
                {
                    "exact_snippets": "Subject is willing ... to comply with all protocol required visits and assessments",
                    "criterion": "willingness to comply with protocol visits and assessments",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject is ... able to comply with all protocol required visits and assessments",
                    "criterion": "ability to comply with protocol visits and assessments",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior chemotherapy and experimental therapy (Poly (ADP-ribose) polymerase (PARP) or checkpoint inhibitor)",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "experimental therapy (Poly (ADP-ribose) polymerase (PARP) or checkpoint inhibitor)",
                    "criterion": "prior experimental therapy with PARP inhibitor or checkpoint inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Discontinuation of enzalutamide or abiraterone less than 3 weeks prior to the start of study medication.",
            "criterions": [
                {
                    "exact_snippets": "Discontinuation of enzalutamide or abiraterone less than 3 weeks prior to the start of study medication.",
                    "criterion": "discontinuation of enzalutamide or abiraterone",
                    "requirements": [
                        {
                            "requirement_type": "time since discontinuation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of impaired adrenal gland function (e.g., Addison's disease, Cushing's syndrome).",
            "criterions": [
                {
                    "exact_snippets": "History of impaired adrenal gland function (e.g., Addison's disease, Cushing's syndrome)",
                    "criterion": "adrenal gland function",
                    "requirements": [
                        {
                            "requirement_type": "impairment history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy",
                    "criterion": "acute treatment-related toxicity (excluding alopecia or neuropathy)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 2 alopecia or neuropathy",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 2 alopecia or neuropathy",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of other malignancy within the previous 3 years, except basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancy within the previous 3 years",
                    "criterion": "history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. History of congestive heart failure New York Heart Association (NYHA) class III or IV or uncontrolled hypertension at screening.",
            "criterions": [
                {
                    "exact_snippets": "History of congestive heart failure New York Heart Association (NYHA) class III or IV",
                    "criterion": "congestive heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension at screening",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Major surgery within 30 days prior to the start of study medication.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 30 days prior to the start of study medication.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History or family history of long QT syndrome, or ECG corrected QT interval equal to and over 500 ms (CTCAE grade 2) at baseline.",
            "criterions": [
                {
                    "exact_snippets": "History ... of long QT syndrome",
                    "criterion": "long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of long QT syndrome",
                    "criterion": "long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "family history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ECG corrected QT interval equal to and over 500 ms (CTCAE grade 2) at baseline",
                    "criterion": "ECG corrected QT interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Prior use of any herbal products known to decrease PSA levels (e.g., PC-SPES or saw palmetto) within 30 days prior to the start of study medication.",
            "criterions": [
                {
                    "exact_snippets": "Prior use of any herbal products known to decrease PSA levels (e.g., PC-SPES or saw palmetto) within 30 days prior to the start of study medication.",
                    "criterion": "use of herbal products known to decrease PSA levels",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to the start of study medication"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Known hypersensitivity to GT0918 or its excipients.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to GT0918",
                    "criterion": "hypersensitivity to GT0918",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... its excipients",
                    "criterion": "hypersensitivity to excipients of GT0918",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Any condition that, in the opinion of the investigator, would impair the subject's ability to comply with study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Any condition that, in the opinion of the investigator, would impair the subject's ability to comply with study procedures.",
                    "criterion": "condition impairing ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Blood transfusion (including blood products) within 1 week of screening.",
            "criterions": [
                {
                    "exact_snippets": "Blood transfusion (including blood products) within 1 week of screening.",
                    "criterion": "blood transfusion (including blood products)",
                    "requirements": [
                        {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Previous history of difficulty swallowing capsules.",
            "criterions": [
                {
                    "exact_snippets": "Previous history of difficulty swallowing capsules",
                    "criterion": "difficulty swallowing capsules",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Use of systemic glucocorticoid (e.g., prednisone, dexamethasone) within 14 days prior to the start of study medication. Inhaled or topical steroids are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Use of systemic glucocorticoid (e.g., prednisone, dexamethasone) within 14 days prior to the start of study medication",
                    "criterion": "systemic glucocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to start of study medication"
                            }
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "systemic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Inhaled or topical steroids are allowed",
                    "criterion": "inhaled or topical steroid use",
                    "requirements": [
                        {
                            "requirement_type": "route of administration",
                            "expected_value": [
                                "inhaled",
                                "topical"
                            ]
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Known gastrointestinal disease or condition that affects the absorption of proxalutamide.",
            "criterions": [
                {
                    "exact_snippets": "Known gastrointestinal disease or condition that affects the absorption of proxalutamide.",
                    "criterion": "gastrointestinal disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on absorption of proxalutamide",
                            "expected_value": "affects"
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Serious concurrent medical condition including CNS disorders.",
            "criterions": [
                {
                    "exact_snippets": "Serious concurrent medical condition",
                    "criterion": "serious concurrent medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including CNS disorders",
                    "criterion": "CNS disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Serious persistent infection within 14 days prior to the start of study medication.",
            "criterions": [
                {
                    "exact_snippets": "Serious persistent infection within 14 days prior to the start of study medication.",
                    "criterion": "serious persistent infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to the start of study medication"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Co-administration of CYP3A4 ligands that serve as substrates or induce or inhibit the enzyme.",
            "criterions": [
                {
                    "exact_snippets": "Co-administration of CYP3A4 ligands that serve as substrates or induce or inhibit the enzyme.",
                    "criterion": "co-administration of CYP3A4 ligands",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": [
                                "substrate",
                                "inducer",
                                "inhibitor"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Inclusion criteria:",
            "criterions": []
        },
        {
            "line": "Exclusion criteria:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}